Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 provides direct-to-patient clinical trial site and patient recruitment services for sponsors seeking to expand trial access beyond traditional research sites. Its updates commonly address the company’s Direct-to-Patient Site, Metasite™ and Patient Recruitment solutions, proprietary technology stack, in-house medical and operational support, nationwide recruitment, telemedicine-enabled oversight, research-grade nursing, and direct-to-patient logistics.
Science 37 news also covers FDA inspection outcomes, data quality and protocol-adherence processes, enrollment contributions in pivotal Phase 3 studies, logistics partnerships for investigational medicinal product delivery, corporate leadership changes, and operational infrastructure supporting clinical research from patients’ homes.
Science 37 appointed Emily Rollins to its Board of Directors as Audit Committee chairperson. Rollins, a retired Deloitte partner, brings over 30 years of experience in corporate governance and audit processes, having advised clients across various growth stages. CEO David Coman expressed enthusiasm for her addition, highlighting her commitment to enhancing clinical research access. Rollins emphasized her shared passion for transforming clinical trials to expedite treatment advancements.
Science 37 has officially debuted on Nasdaq under the ticker symbol SNCE following a successful business combination with LifeSci Acquisition II Corp. The merger resulted in approximately $235 million in cash proceeds, aimed at supporting Science 37's growth initiatives. This funding will enhance the company’s decentralized trial technology platform and improve access to clinical research for underserved populations. The goal is to accelerate patient enrollment and retention through innovative approaches in clinical trials.